PI3K (delta) SELECTIVE INHIBITORS
作者： Congxin Liang
DOI:
关键词:
摘要: Novel PI3K, especially PI3K delta isoform, selective inhibitors are disclosed. The compounds useful in treating disorders related to abnormal or PI3Kδ activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine and neurological disorders.
lens.org 参考文章(8)
Harish Kumar Mysore Nagaraj, Anders Poulsen, Dizhong Chen, Meredith Williams, 2-morpholinylpurines as inhibitors of pi3k ,(2008)
Sam Butterworth, Martin Pass, Edward Jolyon Griffen, 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders ,(2007)
Congxin Liang, Zhigang Li, Pi3k/mtor kinase inhibitors ,(2009)
Claire Chaussade, William Alexander Denny, Peter Robin Shepherd, Gordon William Rewcastle, Swarnalatha Akuratiya Gamage, Substituted pyrimidines and triazines and their use in cancer therapy ,(2009)
Congxin Liang, Zhi-gang Li, PI3K isoform selective inhibitors ,(2009)
Z.A. Knight, K.M. Shokat, Chemically targeting the PI3K family. Biochemical Society Transactions. ,vol. 35, pp. 245- 249 ,(2007) , 10.1042/BST0350245
Anna Claire Giddens, Swarnalatha Akuratiya Gamage, Kit Yee Tsang, Gordon William Rewcastle, Jack Urquhart Flanagan, Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy ,(2010)
Sam Butterworth, Martin Pass, Edward Jolyon Griffen, 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders ,(2007)